Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Richard Musil, Michael Obermeier, Paul Russ & Michael Hamerle. (2015) Weight gain and antipsychotics: a drug safety review. Expert Opinion on Drug Safety 14:1, pages 73-96.
Read now
Read now
Giovanni Martinotti, Gianna Sepede, Maria Signorelli, Eugenio Aguglia & Massimo Di Giannantonio. (2013) Efficacy and safety of fluoxetine monotherapy in bipolar depression: a systematic review. Expert Opinion on Pharmacotherapy 14:8, pages 1065-1075.
Read now
Read now
Steven L Dubovsky. (2013) Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression. Expert Opinion on Drug Metabolism & Toxicology 9:2, pages 207-214.
Read now
Read now
Leslie Citrome. (2013)
Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opinion on Drug Metabolism & Toxicology 9:2, pages 193-206.
Read now
Read now
Articles from other publishers (11)
Janusz K. Rybakowski. (2023) Mood Stabilizers of First and Second Generation. Brain Sciences 13:5, pages 741.
Crossref
Crossref
Adele C. Viguera, Marlene P. Freeman, Lauren A. Kobylski, Ella T. Rossa, Peter Gaccione, David Chitayat, Sonia Hernández-Díaz & Lee S. Cohen. (2023) Risk of Major Malformations Following First-Trimester Exposure to Olanzapine. Journal of Clinical Psychopharmacology 43:2, pages 106-112.
Crossref
Crossref
Janusz K. Rybakowski. (2023) Application of Antipsychotic Drugs in Mood Disorders. Brain Sciences 13:3, pages 414.
Crossref
Crossref
Sagar Suman Panda, Aswini Kumar Behera, Ravi Kumar Venkata Varaha Bera & Sruti Jammula. (2022) Development of a validated liquid chromatography–diode array detection method for simultaneous determination of olanzapine and fluoxetine in their combined formulation: Application to greenness assessment. SEPARATION SCIENCE PLUS 5:5, pages 153-162.
Crossref
Crossref
Darryl Bassett, Philip Boyce, Bill Lyndon, Roger Mulder, Gordon Parker, Richard Porter, Ajeet Singh, Erica Bell, Amber Hamilton, Grace Morris & Gin S. Malhi. (2022) Guidelines for the management of psychosis in the context of mood disorders. Schizophrenia Research 241, pages 187-196.
Crossref
Crossref
Leslie Citrome. (2020) Food and Drug Administration–Approved Treatments for Acute Bipolar Depression. Journal of Clinical Psychopharmacology 40:4, pages 334-338.
Crossref
Crossref
Leslie Citrome. (2014) Treatment of bipolar depression: making sensible decisions. CNS Spectrums 19:S1, pages 1-12.
Crossref
Crossref
Leslie Citrome, Terence A. Ketter, Josephine Cucchiaro & Antony Loebel. (2014) Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 155, pages 20-27.
Crossref
Crossref
Leslie Citrome. (2013) A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach. CNS Drugs 27:11, pages 879-911.
Crossref
Crossref
Marcus T. Silva, Ivan R. Zimmermann, Tais F. Galvao & Mauricio G. Pereira. (2013) Olanzapine plus fluoxetine for bipolar disorder: A systematic review and meta-analysis. Journal of Affective Disorders 146:3, pages 310-318.
Crossref
Crossref
Shefali Srivastava & Terence A. Ketter. (2011) Clinical Relevance of Treatments for Acute Bipolar Disorder: Balancing Therapeutic and Adverse Effects. Clinical Therapeutics 33:12, pages B40-B48.
Crossref
Crossref